RS59395B1 - Jedinjenja n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme - Google Patents

Jedinjenja n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme

Info

Publication number
RS59395B1
RS59395B1 RSP20191116A RS59395B1 RS 59395 B1 RS59395 B1 RS 59395B1 RS P20191116 A RSP20191116 A RS P20191116A RS 59395 B1 RS59395 B1 RS 59395B1
Authority
RS
Serbia
Prior art keywords
arylmethyl
het
heteroaryl
plasma kallikrein
kallikrein inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Rebecca Louise Davie
Hannah Joy Edwards
David Michael Evans
Simon Teanby Hodgson
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52349552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59395(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of RS59395B1 publication Critical patent/RS59395B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
RSP20191116 2014-11-27 2015-11-26 Jedinjenja n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme RS59395B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1421083.5A GB201421083D0 (en) 2014-11-27 2014-11-27 Enzyme inhibitors
PCT/GB2015/053615 WO2016083820A1 (en) 2014-11-27 2015-11-26 N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
EP15804210.1A EP3224256B1 (en) 2014-11-27 2015-11-26 N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,

Publications (1)

Publication Number Publication Date
RS59395B1 true RS59395B1 (sr) 2019-11-29

Family

ID=52349552

Family Applications (3)

Application Number Title Priority Date Filing Date
RSP20191116 RS59395B1 (sr) 2014-11-27 2015-11-26 Jedinjenja n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme
RS20210205A RS61497B1 (sr) 2014-11-27 2015-11-26 Jedinjenja n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme
RS20220301A RS63155B1 (sr) 2014-11-27 2015-11-26 N-((het)arilmetil)-heteroaril-karboksiamidna jedinjenja kao inhibitori kalikrein plazme

Family Applications After (2)

Application Number Title Priority Date Filing Date
RS20210205A RS61497B1 (sr) 2014-11-27 2015-11-26 Jedinjenja n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme
RS20220301A RS63155B1 (sr) 2014-11-27 2015-11-26 N-((het)arilmetil)-heteroaril-karboksiamidna jedinjenja kao inhibitori kalikrein plazme

Country Status (37)

Country Link
US (6) US10364238B2 (sr)
EP (4) EP3556752B1 (sr)
JP (4) JP6653702B2 (sr)
KR (2) KR102267623B1 (sr)
CN (2) CN107108576B (sr)
AR (2) AR102850A1 (sr)
AU (2) AU2015352193B2 (sr)
BR (1) BR112017010882B8 (sr)
CA (1) CA2967894C (sr)
CL (1) CL2017001362A1 (sr)
CO (1) CO2017006230A2 (sr)
CY (3) CY1122255T1 (sr)
DK (3) DK3567037T3 (sr)
EC (1) ECSP17039127A (sr)
ES (3) ES2858082T3 (sr)
GB (1) GB201421083D0 (sr)
HK (1) HK1244268A1 (sr)
HR (3) HRP20220314T1 (sr)
HU (3) HUE057647T2 (sr)
IL (2) IL278182B (sr)
LT (3) LT3556752T (sr)
MA (3) MA47217B1 (sr)
MD (3) MD3556752T2 (sr)
ME (1) ME03514B (sr)
MX (2) MX2020013038A (sr)
MY (1) MY176853A (sr)
NZ (1) NZ731945A (sr)
PH (1) PH12017500901A1 (sr)
PL (3) PL3567037T3 (sr)
PT (3) PT3567037T (sr)
RS (3) RS59395B1 (sr)
RU (2) RU2707870C2 (sr)
SG (2) SG10201907819WA (sr)
SI (3) SI3224256T1 (sr)
TW (2) TWI741377B (sr)
UA (1) UA123087C2 (sr)
WO (1) WO2016083820A1 (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
HUE057106T2 (hu) 2015-10-01 2022-04-28 Biocryst Pharm Inc Humán plazma kallikrein gátlók
GB201609519D0 (en) * 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
PT3464271T (pt) 2016-05-31 2020-07-20 Kalvista Pharmaceuticals Ltd Derivados de pirazol como inibidores da calicreína plasmática
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
US11168080B2 (en) 2017-04-26 2021-11-09 Mitobridge, Inc. Dynamin-1-like protein inhibitors
TW201925188A (zh) * 2017-11-29 2019-07-01 英商卡爾維斯塔製藥有限公司 酶抑制劑
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201719881D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
PT3716952T (pt) * 2017-11-29 2022-04-14 Kalvista Pharmaceuticals Ltd Formas de administração que incluem um inibidor de calicreína plasmática
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
JP2022548696A (ja) 2019-09-18 2022-11-21 武田薬品工業株式会社 血漿カリクレインインヒビター及びその使用
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
WO2021121396A1 (zh) * 2019-12-20 2021-06-24 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途
WO2021175290A1 (zh) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 杂环类化合物
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
EP4232031A1 (en) 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023185634A1 (zh) * 2022-03-30 2023-10-05 南京明德新药研发有限公司 作为血浆激肽释放酶抑制剂的杂环类化合物
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
WO2024025907A1 (en) * 2022-07-29 2024-02-01 Rezolute, Inc. Inhibitors of plasma kallikrein

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
KR100710100B1 (ko) 1999-04-15 2007-04-23 브리스톨-마이어스스퀴브컴파니 환형 단백질 티로신 키나제 억제제
PT1441734E (pt) 2001-10-26 2007-05-31 Isti Di Ric Di Bio Moleco P An Di-hidroxipirimidinocarboxamidas inibidoras da integrase do vih
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
CA2483159C (en) 2002-04-26 2010-08-10 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
EP1426364A1 (en) 2002-12-04 2004-06-09 Aventis Pharma Deutschland GmbH Imidazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
ATE551324T1 (de) 2003-02-03 2012-04-15 Janssen Pharmaceutica Nv Chinolin-amid-derivate als modulatoren von vanilloid-vr1-rezeptoren
CN102813923B (zh) 2003-08-27 2015-04-01 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
ATE518858T1 (de) 2004-09-03 2011-08-15 Yuhan Corp Pyrroloä3,2-cüpyridinderivate und herstellungsverfahren dafür
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
WO2007011328A1 (en) 2005-07-14 2007-01-25 Jackson Kenneth A A method for disabling a hypodermic needle after use
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
GB0606876D0 (en) 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
US20070258976A1 (en) 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
PT2049478E (pt) 2006-07-06 2012-07-16 Glaxo Group Ltd N-fenilmetil-5-oxo-prolina-2-amidas substituídas como antagonistas do recetor p2x7 e seus métodos de utilização
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
BRPI0721298A2 (pt) 2006-12-29 2014-03-25 Abbott Gmbh & Co Kg Composto de carboxamida e seus usos como inibidores de calpaína
WO2008091692A2 (en) 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
JP2010520294A (ja) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
MY154895A (en) 2007-03-30 2015-08-14 Sanofi Aventis Pyrimidine hydrazide compounds as pgds inhibitors
KR20090127435A (ko) 2007-04-03 2009-12-11 글락소 그룹 리미티드 Ｐ2ｘ7 조절제로서의 이미다졸리딘 카르복스아미드 유도체
BRPI0814314A2 (pt) 2007-07-26 2015-05-26 Syngenta Participations Ag Microbiocidas
BRPI0815668A2 (pt) 2007-08-22 2017-05-23 Allergan Inc compostos pirrol tendo atividade biológica antagonista e agonista de receptor de esfingosina-1-fosfato.
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009083553A1 (en) 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
WO2009097141A1 (en) 2008-01-31 2009-08-06 Joslin Diabetes Center Methods for treatment of kallikrein-related disorders
WO2009106980A2 (en) 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
CN102149680B (zh) 2008-07-08 2014-12-10 第一三共株式会社 含氮芳族杂环化合物
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
MX2012006913A (es) 2009-12-18 2012-08-23 Activesite Pharmaceuticals Inc Profarmacos de inhibidores de calicreina plasmatica.
JP2011157349A (ja) 2010-01-07 2011-08-18 Daiichi Sankyo Co Ltd 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
JP5709902B2 (ja) 2010-01-28 2015-04-30 ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー トリプシン様セリンプロテアーゼ阻害剤、ならびにその調製および使用
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2458315B1 (de) 2010-11-25 2017-01-04 Balcke-Dürr GmbH Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012174362A1 (en) 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8952180B2 (en) 2011-09-27 2015-02-10 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
EP2807157A1 (en) 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9846160B2 (en) 2012-02-27 2017-12-19 Board Of Regents, The University Of Texas Systems Ganglioside GD2 as a marker and target on cancer stem cells
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
WO2014108406A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
EP3421036B8 (en) 2013-03-15 2020-12-30 Verseon International Corporation Multisubstituted aromatic compounds as serine protease inhibitors
US9533987B2 (en) 2013-05-23 2017-01-03 Kalvista Pharmaceuticals Limited Heterocyclic derivates
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
EP3033336B1 (en) 2013-08-14 2018-05-30 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
BR112016015449A8 (pt) 2013-12-30 2020-06-09 Lifesci Pharmaceuticals Inc compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
NZ724250A (en) 2014-03-07 2022-02-25 Biocryst Pharm Inc Human plasma kallikrein inhibitors
WO2015171527A1 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
WO2015171526A2 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Tricyclic pyrazolopyridine compounds
EA035410B1 (ru) 2014-07-16 2020-06-09 Лайфсай Фармасьютикалс, Инк. Терапевтические соединения-ингибиторы
DK3182962T3 (da) 2014-08-22 2023-09-18 Biocryst Pharm Inc Compositions and uses of amidine derivatives
MX2017003624A (es) 2014-09-17 2017-07-13 Verseon Corp Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
EP3317241A4 (en) 2015-07-01 2019-01-23 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
WO2017001926A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Therapeutic inhibitory compounds
US10640486B2 (en) 2015-10-27 2020-05-05 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US10399961B2 (en) 2015-10-27 2019-09-03 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
PT3464271T (pt) 2016-05-31 2020-07-20 Kalvista Pharmaceuticals Ltd Derivados de pirazol como inibidores da calicreína plasmática
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
TW201925188A (zh) 2017-11-29 2019-07-01 英商卡爾維斯塔製藥有限公司 酶抑制劑

Also Published As

Publication number Publication date
IL278182A (en) 2020-11-30
BR112017010882B1 (pt) 2023-10-31
EP3556752B1 (en) 2022-01-05
US11084809B2 (en) 2021-08-10
NZ770256A (en) 2021-11-26
RU2017122364A (ru) 2018-12-27
SI3224256T1 (sl) 2019-12-31
KR102267623B1 (ko) 2021-06-18
AR121273A2 (es) 2022-05-04
EP3556752A1 (en) 2019-10-23
US10611758B2 (en) 2020-04-07
RU2707870C2 (ru) 2019-12-02
US11001578B2 (en) 2021-05-11
PT3224256T (pt) 2019-09-23
CL2017001362A1 (es) 2018-02-09
RU2019131174A (ru) 2019-10-10
GB201421083D0 (en) 2015-01-14
EP3224256A1 (en) 2017-10-04
HUE057647T2 (hu) 2022-05-28
US20190300517A1 (en) 2019-10-03
SI3567037T1 (sl) 2021-04-30
MY176853A (en) 2020-08-24
US20180319782A1 (en) 2018-11-08
JP2022180520A (ja) 2022-12-06
MD3224256T2 (ro) 2019-12-31
NZ731945A (en) 2021-07-30
ES2908303T3 (es) 2022-04-28
AU2019240616A1 (en) 2019-10-17
CY1125214T1 (el) 2023-06-09
US20200361923A1 (en) 2020-11-19
ME03514B (me) 2020-04-20
LT3224256T (lt) 2019-09-25
HUE053317T2 (hu) 2021-06-28
DK3567037T3 (da) 2021-02-08
UA123087C2 (uk) 2021-02-17
EP4039681A1 (en) 2022-08-10
MA47217A (fr) 2019-11-13
TWI686383B (zh) 2020-03-01
CA2967894A1 (en) 2016-06-02
BR112017010882B8 (pt) 2023-11-14
AU2019240616B2 (en) 2021-07-29
LT3567037T (lt) 2021-02-25
JP2021185138A (ja) 2021-12-09
MA41014B1 (fr) 2019-09-30
CO2017006230A2 (es) 2017-09-11
TW202026285A (zh) 2020-07-16
EP3224256B1 (en) 2019-07-03
AU2015352193A1 (en) 2017-06-08
RS63155B1 (sr) 2022-05-31
US11198691B2 (en) 2021-12-14
HK1244268A1 (zh) 2018-08-03
KR20210075227A (ko) 2021-06-22
PL3556752T3 (pl) 2022-05-02
SI3556752T1 (sl) 2022-05-31
PH12017500901A1 (en) 2017-12-18
US20200199116A1 (en) 2020-06-25
JP6995101B2 (ja) 2022-01-14
BR112017010882A2 (pt) 2017-12-26
JP2017535568A (ja) 2017-11-30
HUE047425T2 (hu) 2020-04-28
ES2745815T3 (es) 2020-03-03
CN107108576B (zh) 2020-03-10
DK3556752T3 (da) 2022-03-07
US20220289729A1 (en) 2022-09-15
EP3567037B1 (en) 2020-12-23
IL278182B (en) 2022-09-01
CN107108576A (zh) 2017-08-29
PL3567037T3 (pl) 2021-06-14
MD3556752T2 (ro) 2022-07-31
DK3224256T3 (da) 2019-09-23
US20190330200A1 (en) 2019-10-31
KR102496404B1 (ko) 2023-02-06
PT3567037T (pt) 2021-02-23
KR20170090451A (ko) 2017-08-07
SG11201703988PA (en) 2017-06-29
ECSP17039127A (es) 2017-12-01
CA2967894C (en) 2024-01-30
MX2020013038A (es) 2022-12-09
MA47217B1 (fr) 2021-04-30
SG10201907819WA (en) 2019-09-27
MA52063A (fr) 2021-05-26
CY1124046T1 (el) 2022-05-27
ES2858082T3 (es) 2021-09-29
US10364238B2 (en) 2019-07-30
CY1122255T1 (el) 2020-11-25
AU2015352193B2 (en) 2019-10-10
HRP20220314T1 (hr) 2022-05-13
MD3567037T2 (ro) 2021-05-31
MX2017006823A (es) 2017-09-27
TW201625548A (zh) 2016-07-16
AR102850A1 (es) 2017-03-29
LT3556752T (lt) 2022-03-10
PT3556752T (pt) 2022-04-14
CN110577519A (zh) 2019-12-17
TWI741377B (zh) 2021-10-01
JP6653702B2 (ja) 2020-02-26
HRP20191524T1 (hr) 2019-11-29
JP7148683B2 (ja) 2022-10-05
IL252287A0 (en) 2017-07-31
MA52063B1 (fr) 2022-01-31
PL3224256T3 (pl) 2020-01-31
MA41014A (fr) 2017-10-04
RU2017122364A3 (sr) 2019-06-19
EP3567037A1 (en) 2019-11-13
HRP20210350T1 (hr) 2021-04-16
IL252287B (en) 2020-11-30
RS61497B1 (sr) 2021-03-31
WO2016083820A1 (en) 2016-06-02
JP2020033357A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
IL278182A (en) N-((het)arylmethyl)-heteroaryl-carboxamide compounds as plasma kallikrein inhibitors
IL287517A (en) Benzimidazole compounds as c-kit inhibitors
HK1231480A1 (zh) 作為 抑制劑的吲唑化合物
HK1231411A1 (zh) 作為 抑制劑的取代的吲唑化合物
PL3224255T3 (pl) Związki n-((het)arylometylo)heteroarylokarboksyamidów jako inhibitory kalikreiny osoczowej
PT3371190T (pt) Compostos heterocíclicos como inibidores de pi3k-gamma
HK1251876A1 (zh) 作為atx抑制劑的二環化合物
HK1246787A1 (zh) 作為atx抑制劑的二環化合物